The ACIP develops recommendations on how to use vaccines to control disease in the United States.
The Committee’s recommendations are forwarded to CDC’s Director for approval. Once the ACIP recommendations have been reviewed and approved by the CDC Director and the U.S. Department of Health and Human Services, they are published in CDC’s Morbidity and Mortality Weekly Report (MMWR). The MMWR publication represents the final and official CDC recommendations for immunization of the U.S. population.
Professional organizations that work with the ACIP to develop the annual childhood and adult schedules include the American Academy of Pediatrics (AAP), the American Academy of Family Physicians (AAFP), the American College of Obstetricians and Gynecologists (ACOG), and the American College of Physicians (ACP).
- ACIP Recommendations
Complete list of ACIP recommendations published in the MMWR.
- Immunization Schedules
Links to the childhood, adolescent, catch-up, and adult immunization schedules; plus vaccine recording and screening forms.
- ACIP Shared Clinical Decision-Making FAQs
Frequently asked questions about ACIP’s recommendations based on shared clinical decision-making
ACIP approved the following recommendations by majority vote at its October 19-20, 2022 meeting:
- Approve the Recommended Child and Adolescent Immunization Schedule, United States, 2023 and Recommended Adult Immunization Schedule, United States, 2023.
- Adults with an immunocompromising condition, cochlear implant, or cerebrospinal fluid leak who have received both PCV13 and PPSV23 with incomplete vaccination status are recommended to complete their pneumococcal vaccine series by receiving either a dose of PCV20 at least 5 years after the last pneumococcal vaccine dose or PPSV23 as previously recommended.
- Shared clinical decision-making is recommended regarding administration of PCV20 for adults aged ≥65 years who completed their vaccine series with both PCV13 and PPSV23. If a decision to administer PCV20 is made, a dose of PCV20 is recommended at least 5 years after the last pneumococcal vaccine dose.
- Adults who have received PCV13 only are recommended to receive a dose of PCV20 at least 1 year after the PCV13 dose or PPSV23 as previously recommended to complete their pneumococcal vaccine series.
These recommendations have been adopted by the CDC Director and are now official. They will be published in MMWR in the coming months.